Top

Digestive Diseases and Sciences

Published in:

01-11-2012 | Original Article

Anti-Saccharomyces cerevisiae Antibodies Associate with Phenotypes and Higher Risk for Surgery in Crohn’s Disease: A Meta-Analysis

Authors: Zhaoxia Zhang, Chen Li, Xinmei Zhao, Chaolan Lv, Qiong He, Shan Lei, Yandong Guo, Fachao Zhi

Published in: Digestive Diseases and Sciences | Issue 11/2012

Abstract

Background

Recent studies suggested that anti-Saccharomyces cerevisiae antibody (ASCA) status was associated with diagnostic findings, stratified classification phenotypes, disease activity and clinical course of Crohn’s disease (CD). However, the relationship between ASCA status and phenotypes of CD remains controversial in these studies.

Aims

The purpose of this study was to evaluate whether ASCA status is associated with the phenotypes and the risk of surgery in diverse populations in CD.

Methods

We conducted a meta-analysis of studies assessing the association of ASCA status with phenotypes and risk of surgery in CD. Three independent reviewers undertook data extraction. We pooled odds ratios separately for the cohort and case–control studies.

Results

We identified ten cohort studies (n = 2,365) and 14 case–control studies (n = 1,887) that investigated the association of ASCA status with phenotypes and risk of surgery in CD. The meta-analysis of the cohort studies showed significant association between the ASCA-positive status and higher risk of early-onset age (OR 2.25, 95 % CI 1.41–3.57, P < 0.001), ileal involvement disease (1.70, 1.05–2.77, P = 0.03), complicated disease behavior (2.09, 1.71–2.57, P < 0.001), perianal disease (1.49, 1.14–1.94, P = 0.004), and risk for surgery (1.61, 1.29–2.01, P < 0.001). Meta-analysis of the case–control studies also showed a significantly higher risk in ileal involvement disease (1.77, 1.25–2.49, P = 0.001), complicated disease behavior (2.13, 1.70–2.68, P < 0.001), perianal disease (1.96, 1.38–2.78, P < 0.001), and risk for surgery (1.71, 1.17–2.49, P = 0.005), except for the early-onset age (1.16, 0.80–1.69, P = 0.44).

Conclusions

This meta-analysis indicated that positive ASCA status is a risk factor for early-onset age, ileal involvement, complicated behavior, perianal disease and requirement for surgery in CD.

Friedman S, Blumberg RS. Inflammatory bowel disease. In: Kasper DL, Braunwald E, Fauci AS, et al., eds. Harrison’s Principles of Internal Medicine, 16th ed. Seoul: McGraw-Hill; 2005:1776–1789.

Main J, McKenzie H, Yeaman GR, et al. Antibody to Saccharomyces cerevisiae (bakers’ yeast) in Crohn’s disease. Br Med J. 1988;297:1105–1106.CrossRef

Sendid B, Colombel JF, Jacquinot PM, et al. Specific antibody response to oligomannosidic epitopes in Crohn’s disease. Clin Diagn Lab Immunol. 1996;3:219–226.PubMedCentralPubMed

Vasiliauskas EA, Kam LY, Karp LC, et al. Marker antibody expression stratifies Crohn’s disease into immunologically homogenous subgroups with distinct clinical characteristics. Gut. 2000;47:487–496.PubMedCrossRef

Vermeire S, Peeters M, Vlietinck R, et al. Anti-Saccharomyces antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm Bowel Dis. 2001;7:8–15.PubMedCrossRef

Ruemmele FM, Targan SR, Levy G, et al. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology. 1998;115:822–829.PubMedCrossRef

Walker LJ, Aldhous MC, Drummond HE, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn’s disease are associated with disease severity but not NOD2/CARD15 mutations. Clin Exp Immunol. 2004;135:490–496.PubMedCentralPubMedCrossRef

Forcione DG, Rosen MJ, Kisiel JB, et al. Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn’s disease. Gut. 2004;53:1117–1122.PubMedCrossRef

Arnott ID, Landers CJ, Nimmo EJ, et al. Sero-reactivity to microbial components in Crohn’s disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol. 2004;99:2376–2384.PubMedCrossRef

10.

Kim BC, Park S, Han J, et al. Clinical significance of anti-Saccharomyces cerevisiae antibody (ASCA) in Korean patients with Crohn’s disease and its relationship to the disease clinical course. Dig Liver Dis. 2007;39:610–616.PubMedCrossRef

11.

Halfvarson J, Standaert-Vitse A, Jarnerot G, et al. Anti-Saccharomyces cerevisiae antibodies in twins with inflammatory bowel disease. Gut. 2005;54:1237–1243.PubMedCrossRef

12.

Norman GL. Anti-Saccharomyces cerevisiae antibodies in inflammatory bowel disease. Clin Appl Immunol Rev. 2001;2:45–63.CrossRef

13.

Hisabe T, Matsui T, Sakurai T, et al. Anti-Saccharomyces cerevisiae antibodies in Japanese patients with inflammatory bowel disease: diagnostic accuracy and clinical value. J Gastroenterol. 2003;38:121–126.PubMedCrossRef

14.

Suzuki H, Fukuda Y, Koizuka H, et al. Dietary antigens in Crohn’s disease: antibodies to porcine pancreatic amylase. Am J Gastroenterol. 2008;103:656–664.PubMedCrossRef

15.

Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. The Standards for Reporting of Diagnostic Accuracy Group. Croat Med J. 2003;44:635–638.PubMed

16.

Whiting P, Rutjes AW, Reitsma JB, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25.PubMedCentralPubMedCrossRef

17.

Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn’s disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000;6:8–15.PubMedCrossRef

18.

Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749–753.PubMedCrossRef

19.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188.PubMedCrossRef

20.

Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560.PubMedCrossRef

21.

Thornton A, Lee P. Publication bias in meta-analysis: its causes and consequences. J Clin Epidemiol. 2000;53:207–216.PubMedCrossRef

22.

Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634.PubMedCrossRef

23.

Koutroubakis IE, Petinaki E, Mouzas IA, et al. Anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic autoantibodies in Greek patients with inflammatory bowel disease. Am J Gastroenterol. 2001;96:449–454.PubMed

24.

Bernstein CN, Orr K, Blanchard JF, et al. Development of an assay for antibodies to Saccharomyces cerevisiae: easy, cheap and specific for Crohn’s disease. Can J Gastroenterol. 2001;15:499–504.PubMed

25.

Sostegni R, Daperno M, Ercole E, et al. Detection of anti-Saccharomyces cerevisiae antibodies in Crohn’s disease: is it a reliable diagnostic and prognostic marker? Dig Liver Dis. 2001;33:755–761.PubMedCrossRef

26.

Smith BR, Arnott ID, Drummond HE, et al. Disease location, anti-Saccharomyces cerevisiae antibody, and NOD2/CARD15 genotype influence the progression of disease behavior in Crohn’s disease. Inflamm Bowel Dis. 2004;10:521–528.PubMedCrossRef

27.

Linskens RK, Mallant-Hent RC, Murillo LS, et al. Genetic and serological markers to identify phenotypic subgroups in a Dutch Crohn’s disease population. Dig Liver Dis. 2004;36:29–34.PubMedCrossRef

28.

Annese V, Piepoli A, Perri F, et al. Anti-Saccharomyces cerevisiae mannan antibodies in inflammatory bowel disease: comparison of different assays and correlation with clinical features. Aliment Pharmacol Ther. 2004;20:1143–1152.PubMedCrossRef

29.

Kaila B, Orr K, Bernstein CN. The anti-Saccharomyces cerevisiae antibody assay in a province-wide practice: accurate in identifying cases of Crohn’s disease and predicting inflammatory disease. Can J Gastroenterol. 2005;19:717–721.PubMed

30.

Preda CM, Diculescu M, Mirea V, et al. Significance of anti-Saccharomyces cerevisiae antibodies (ASCA) in patients with inflammatory bowel diseases in Romania. Rom J Gastroenterol. 2005;14:23–26.PubMed

31.

Amre DK, Lu SE, Costea F, et al. Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn’s disease patients. Am J Gastroenterol. 2006;101:645–652.PubMedCrossRef

32.

Dubinsky MC, Lin YC, Dutridge D, et al. Serum immune responses predict rapid disease progression among children with Crohn’s disease: immune responses predict disease progression. Am J Gastroenterol. 2006;101:360–367.PubMedCentralPubMedCrossRef

33.

Papp M, Altorjay I, Norman GL, et al. Seroreactivity to microbial components in Crohn’s disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients. Inflamm Bowel Dis. 2007;13:984–992.PubMedCrossRef

34.

Desplat-Jégo S, Johanet C, Escande A, et al. Update on anti-Saccharomyces cerevisiae antibodies, anti-nuclear associated anti-neutrophil antibodies and antibodies to exocrine pancreas detected by indirect immunofluorescence as biomarkers in chronic inflammatory bowel diseases: results of a multicenter study. World J Gastroenterol. 2007;13:2312–2318.PubMed

35.

Dassopoulos T, Frangakis C, Cruz-Correa M, et al. Antibodies to Saccharomyces cerevisiae in Crohn’s disease: higher titers are associated with a greater frequency of mutant NOD2/CARD15 alleles and with a higher probability of complicated disease. Inflamm Bowel Dis. 2007;13:143–151.PubMedCrossRef

36.

Dubinsky MC, Kugathasan S, Mei L, et al. Increased immune reactivity predicts aggressive complicating Crohn’s disease in children. Clin Gastroenterol Hepatol. 2008;6:1105–1111.PubMedCentralPubMedCrossRef

37.

Schoepfer AM, Schaffer T, Mueller S, et al. Phenotypic associations of Crohn’s disease with antibodies to flagellins A4-Fla2 and Fla-X, ASCA, p-ANCA, PAB, and NOD2 mutations in a Swiss Cohort. Inflamm Bowel Dis. 2009;15:1358–1367.PubMedCentralPubMedCrossRef

38.

Solberg IC, Lygren I, Cvancarova M, et al. Predictive value of serologic markers in a population-based Norwegian cohort with inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:406–414.PubMedCrossRef

39.

Russell RK, Ip B, Aldhous MC, et al. Anti-Saccharomyces cerevisiae antibodies status is associated with oral involvement and disease severity in Crohn disease. J Pediatr Gastroenterol Nutr. 2009;48:161–167.PubMedCrossRef

40.

Dassopoulos T, Nguyen GC, Talor MV, et al. NOD2 mutations and anti-Saccharomyces cerevisiae antibodies are risk factors for Crohn’s disease in African Americans. Am J Gastroenterol. 2010;105:378–386.PubMedCentralPubMedCrossRef

41.

Zhou F, Xia B, Wang F, et al. The prevalence and diagnostic value of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies in patients with inflammatory bowel disease in mainland China. Clin Chim Acta. 2010;411:1461–1465.PubMedCrossRef

42.

Demirsoy H, Ozdil K, Ersoy O, et al. Anti-pancreatic antibody in Turkish patients with inflammatory bowel disease and first-degree relatives. World J Gastroenterol. 2010;16:5732–5738.PubMedCrossRef

43.

Van Assche G, Rutgeerts P. Medical management of postoperative recurrence in Crohn’s disease. Gastroenterol Clin North Am. 2004;33:347–360.PubMedCrossRef

44.

Rutgeerts P. Strategies in the prevention of post-operative recurrence in Crohn’s disease. Best Pract Res Clin Gastroenterol. 2003;17:63–73.PubMedCrossRef

45.

Standaert-Vitse A, Jouault T, Vandewalle P, et al. Candida albicans is an immunogen for anti-Saccharomyces cerevisiae antibody markers of Crohn’s disease. Gastroenterology. 2006;130:1764–1775.PubMedCrossRef

46.

Seibold F, Konrad A, Flogerzi B, et al. Genetic variants of the mannan-binding lectin are associated with immune reactivity to mannans in Crohn’s disease. Gastroenterology. 2004;127:1076–1084.PubMedCrossRef

47.

Török HP, Glas J, Hollay HC, et al. Serum antibodies in first-degree relatives of patients with IBD: a marker of disease susceptibility? A follow-up pilot-study after 7 years. Digestion. 2005;72:119–123.PubMedCrossRef

48.

Glas J, Török HP, Vilsmaier F, et al. Anti-Saccharomyces cerevisiae antibodies in patients with inflammatory bowel disease and their first-degree relatives: potential clinical value. Digestion. 2002;66:173–177.PubMedCrossRef

49.

Papp M, Altorjay I, Dotan N, et al. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Am J Gastroenterol. 2008;103:665–681.PubMedCrossRef

50.

Hugot JP, Laurent-Puig P, Gower-Rousseau C, et al. Mapping for susceptibility locus for Crohn’s disease on chromosome 16. Nature. 1996;379:821–823.PubMedCrossRef

51.

Cruyssen BV, Peeters H, Hoffman IE, et al. CARD15 polymorphisms are associated with anti-Saccharomyces cerevisiae antibodies in Caucasian Crohn’s disease patients. Clin Exp Immunol. 2005;140:354–359.PubMedCentralPubMedCrossRef

52.

Mow WS, Vasiliauskas EA, Lin YC, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn’s disease. Gastroenterology. 2004;126:414–424.PubMedCrossRef

53.

Abreu MT, Taylor KD, Lin YC, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn’s disease. Gastroenterology. 2002;123:679–688.PubMedCrossRef

54.

Henckaerts L, Pierik M, Joossens M, et al. Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease. Gut. 2007;56:1536–1542.PubMedCrossRef

55.

Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol. 2006;12:6102–6108.PubMed

56.

Devlin SM, Yang H, Ippoliti A, et al. NOD2 variants and antibody response o microbial antigens in Crohn’s disease patients and their unaffected relatives. Gastroenterology. 2007;132:576–586.PubMedCrossRef

57.

Reumaux D, Sendid B, Poulain D, et al. Serological markers in inflammatory bowel diseases. Best Pract Res Clin Gastroenterol. 2003;17:19–35.PubMedCrossRef

Title: Anti-Saccharomyces cerevisiae Antibodies Associate with Phenotypes and Higher Risk for Surgery in Crohn’s Disease: A Meta-Analysis
Authors: Zhaoxia Zhang
Chen Li
Xinmei Zhao
Chaolan Lv
Qiong He
Shan Lei
Yandong Guo
Fachao Zhi
Publication date: 01-11-2012
Publisher: Springer US
Published in: Digestive Diseases and Sciences / Issue 11/2012
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-012-2244-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Aims

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2012

Menarche in Pediatric Patients with Crohn’s Disease

Alagille Syndrome: A Rare Disease in an Adolescent

Elevation of Alanine Transaminase and Markers of Liver Fibrosis After a Mixed Meal Challenge in Individuals with Type 2 Diabetes

Current Advantages in the Application of Proteomics in Inflammatory Bowel Disease

Missense Mutations in MLH1, MSH2, KRAS, and APC Genes in Colorectal Cancer Patients in Malaysia

Acute Fulminant Hepatic Failure Associated with Parvovirus B19 Infection in an Immunocompetent Adult

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials